secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2024-09-10T23:59:59+00:00
Accession:  0001193125-24-216321
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian's veligrotug Phase 3 THRIVE meets all endpoints; 70% proptosis responder rate vs 5% placebo (p<0.0001)
--------------------------------------------------------------------------------

- Proptosis responder rate 70% drug vs 5% placebo; mean reduction 2.9 mm vs 0.5 mm (p<0.0001).
- Complete diplopia resolution 54% vs 12%; CAS 0/1 achieved by 64% vs 18% (both p<0.0001).
- No treatment-related serious AEs; 5.5% placebo-adjusted hearing impairment rate; 4% discontinuation rate.
- THRIVE-2 enrollment complete; topline data year-end 2024; BLA submission on track for 2H 2025.
- Cash $571.4M as of June 30, 2024; runway into 2H 2026; VRDN-003 phase 3 REVEAL trials initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312524216321/0001193125-24-216321-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312524216321/d885072d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-216321

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer